RESUMEN
Background: High-dose methotrexate (HD-MTX) therapy is widely implemented for leukemia, osteosarcoma, and lymphoma. Although various measures have been taken to avoid toxicity from high serum MTX concentrations, there are many cases of delayed elimination of MTX. Objective: We suspected that delayed elimination of serum MTX was caused by unknown interactions between MTX and concomitant drugs. Methods: Concerning concomitant drugs in the case of delayed elimination of MTX, we performed screening tests in 35 patients who had undergone HD-MTX therapy. We then investigated the risk factors for delayed MTX elimination in 94 patients with leukemia, lymphoma, or osteosarcoma retrospectively. Results: The percentages of concomitant use of Stronger Neo-Minophagen C (SNMC), a glycyrrhizin preparation, and vincristine were higher in the delayed group. The percentage of delayed MTX elimination in patients receiving HD-MTX therapy was 41%. Multiple logistic regression analysis revealed that the concomitant use of SNMC solely was a significant risk factor for delayed MTX (odds ratio = 12.20; 95% CI = 1.06-139.84). Conclusion and Relevance: Concomitant use of SNMC was shown to be related to delayed elimination of serum MTX, and our results suggested a previously unknown drug-drug interaction between MTX and SNMC.
Asunto(s)
Monitoreo de Drogas/métodos , Metotrexato/administración & dosificación , Metotrexato/sangre , Cisteína/administración & dosificación , Cisteína/sangre , Cisteína/uso terapéutico , Combinación de Medicamentos , Interacciones Farmacológicas , Femenino , Glicina/administración & dosificación , Glicina/sangre , Glicina/uso terapéutico , Ácido Glicirretínico/administración & dosificación , Ácido Glicirretínico/análogos & derivados , Ácido Glicirretínico/sangre , Ácido Glicirretínico/uso terapéutico , Humanos , Leucemia/sangre , Leucemia/tratamiento farmacológico , Modelos Logísticos , Linfoma/sangre , Linfoma/tratamiento farmacológico , Masculino , Tasa de Depuración Metabólica , Metotrexato/uso terapéutico , Osteosarcoma/sangre , Osteosarcoma/tratamiento farmacológico , Estudios Retrospectivos , Factores de Riesgo , Vincristina/administración & dosificación , Vincristina/sangre , Vincristina/uso terapéuticoRESUMEN
Osteosarcoma (OSA) is a malignant tumor of middle-aged dogs and adolescent humans. The clinical outcome of OSA has not improved over more than three decades, and dogs typically succumb to metastatic disease within 6 months despite tumor resection through limb amputation and adjuvant chemotherapy. Therefore, undetectable tumor cells with potential to form metastases are present at diagnosis. An assay to identify canine immortalized and primary OSA cells through flow cytometric detection of intracellular collagen 1 (Col I) and osteocalcin was optimized, and applied to blood samples from tumor-bearing dogs for detection of circulating tumor cells (CTCs). Spiking variable number of OSA cells into normal dog blood recovered 50-60% of Col I positive cells with high forward and variable side light scatter. An algorithm to exclude nonviable, doublet, and autofluorescent cells was applied to sequential blood samples from three dogs obtained prior to and after limb amputation, and at approximately, triweekly intervals over 121, 142, and 183 days of chemotherapy, respectively. Dogs had >100 CTC/106 leukocytes prior to amputation, variably frequent CTC during chemotherapy, and an increase up to 4,000 CTC/106 leukocytes within 4 weeks before overt metastases or death. Sorted CTCs were morphologically similar to direct tumor aspirates and positive for Col I. Although preliminary, findings suggest that CTCs are frequent in canine OSA, more numerous than carcinoma CTC in humans, and that an increase in CTC frequency may herald clinical deterioration. This assay may enable enumeration and isolation of OSA CTC for prognostic and functional studies, respectively. © 2019 International Society for Advancement of Cytometry.
Asunto(s)
Neoplasias Óseas/veterinaria , Enfermedades de los Perros/diagnóstico por imagen , Citometría de Flujo/métodos , Células Neoplásicas Circulantes/metabolismo , Osteosarcoma/veterinaria , Amputación Quirúrgica , Animales , Neoplasias Óseas/sangre , Neoplasias Óseas/diagnóstico por imagen , Neoplasias Óseas/tratamiento farmacológico , Línea Celular Tumoral , Colágeno/metabolismo , Enfermedades de los Perros/sangre , Enfermedades de los Perros/tratamiento farmacológico , Perros , Procesamiento de Imagen Asistido por Computador , Leucocitos/metabolismo , Células Neoplásicas Circulantes/efectos de los fármacos , Células Neoplásicas Circulantes/patología , Osteocalcina/metabolismo , Osteosarcoma/sangre , Osteosarcoma/diagnóstico por imagen , Osteosarcoma/tratamiento farmacológico , PronósticoRESUMEN
The form of selenium appears to be important for preventing cancer in humans. Here, we evaluated selenium levels in the serum and bone tissue samples from osteosarcoma patients using atomic absorption spectrometry. The in vitro effects of Se-methylselenocysteine (Se-MSC) on growth, cell cycle status, and apoptosis of osteosarcoma cells were assessed using the WST-1 assay, Hoechst 33342/propidium iodide staining, and flow cytometry, respectively. In osteosarcoma cases, the mean serum selenium levels in osteosarcoma tissue and normal bone were 0.08 mg/kg and 0.03 mg/kg, respectively (P < 0.05). Serum selenium levels in osteosarcoma and non-osteosarcoma cases were 0.09 mg/L and 0.08 mg/L, respectively (P > 0.05). Se-MSC-treated MG63 cells showed altered cellular morphology, decreased viability in a time- and dose-dependent manner, and an increase in the sub-G1 cell population. Se-MSC also downregulated Bcl-2 expression and upregulated Bax. Se-MSC inhibited the proliferation of the drug-resistant osteosarcoma cell line Saos-2/MTX300 and enhanced the inhibitory effect of pirarubicin on MG63 cells. Our data demonstrate that selenium levels are significantly higher in osteosarcoma tissue than normal bone tissue in osteosarcoma patients. The results also support the anticancer effects of Se-MSC in osteosarcoma. Further development of Se-MSC as an ancillary chemotherapy agent in osteosarcoma is warranted.
Asunto(s)
Anticarcinógenos/farmacología , Neoplasias Óseas/prevención & control , Osteosarcoma/prevención & control , Selenio/sangre , Selenocisteína/análogos & derivados , Adolescente , Adulto , Anciano , Apoptosis/efectos de los fármacos , Western Blotting , Neoplasias Óseas/sangre , Ciclo Celular/efectos de los fármacos , Línea Celular Tumoral , Niño , Evaluación Preclínica de Medicamentos , Femenino , Genes bcl-2/efectos de los fármacos , Humanos , Masculino , Persona de Mediana Edad , Osteosarcoma/sangre , Selenocisteína/farmacología , Adulto Joven , Proteína X Asociada a bcl-2/efectos de los fármacosRESUMEN
BACKGROUND: Glucarpidase rapidly reduces methotrexate plasma concentrations in patients experiencing methotrexate-induced renal dysfunction. Debate exists regarding the role of glucarpidase in therapy given its high cost. The use of reduced-dose glucarpidase has been reported, and may allow more institutions to supply this drug to their patients. This report explores the relationship between glucarpidase dosage and patient outcomes in pediatric oncology patients. METHODS: The authors evaluated data from 26 patients who received glucarpidase after high-dose methotrexate. Decrease in plasma methotrexate concentrations and time to renal recovery were evaluated for an association with glucarpidase dosage, which ranged from 13 to 90 units/kg. RESULTS: No significant relationship was found between glucarpidase dosage (units/kg) and percent decrease in methotrexate plasma concentrations measured by TDx (P > 0.1) or HPLC (P > 0.5). Patients who received glucarpidase dosages <50 units/kg had a median percent reduction in methotrexate plasma concentration of 99.4% (range, 98-100) measured by HPLC compared to a median percent reduction of 99.4% (range, 77.2-100) in patients who received ≥50 units/kg. Time to SCr recovery was not related to glucarpidase dosage (P > 0.8). CONCLUSIONS: The efficacy of glucarpidase in the treatment of HDMTX-induced kidney injury was not dosage-dependent in this retrospective analysis of pediatric oncology patients.
Asunto(s)
Lesión Renal Aguda/tratamiento farmacológico , Antimetabolitos Antineoplásicos/efectos adversos , Metotrexato/antagonistas & inhibidores , gamma-Glutamil Hidrolasa/administración & dosificación , Lesión Renal Aguda/sangre , Lesión Renal Aguda/inducido químicamente , Adolescente , Antimetabolitos Antineoplásicos/administración & dosificación , Antimetabolitos Antineoplásicos/farmacocinética , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Neoplasias Óseas/sangre , Neoplasias Óseas/complicaciones , Neoplasias Óseas/tratamiento farmacológico , Niño , Preescolar , Creatinina/sangre , Relación Dosis-Respuesta a Droga , Esquema de Medicación , Costos de los Medicamentos , Evaluación de Medicamentos , Femenino , Neoplasias Hematológicas/sangre , Neoplasias Hematológicas/complicaciones , Neoplasias Hematológicas/tratamiento farmacológico , Humanos , Inactivación Metabólica/efectos de los fármacos , Infusiones Intravenosas , Inyecciones Intravenosas , Leucovorina/administración & dosificación , Masculino , Metotrexato/administración & dosificación , Metotrexato/efectos adversos , Metotrexato/farmacocinética , Osteosarcoma/sangre , Osteosarcoma/complicaciones , Osteosarcoma/tratamiento farmacológico , Proteínas Recombinantes/administración & dosificación , Proteínas Recombinantes/economía , Proteínas Recombinantes/uso terapéutico , Recuperación de la Función , Estudios Retrospectivos , Adulto Joven , gamma-Glutamil Hidrolasa/economía , gamma-Glutamil Hidrolasa/uso terapéuticoRESUMEN
Osteosarcoma (OS) patients who suffer manipulation therapy (MT) prior to diagnosis resulted in poor prognosis with increasing metastasis or recurrence rate. The aim of the study is to establish an in vivo model to identify the effects of MT on OS. The enrolled 235 OS patients were followed up in this study. In vivo nude mice model with tibia injection of GFP-labeled human OS cells were randomly allocated into MT(+) that with repeated massage on tumor site twice a week and no treatment as MT(-) group. The five-year survival, metastasis and recurrence rates were recorded in clinical subjects. X-ray plainfilm, micro-PET/CT scan, histopathology, serum metalloproteinase 2 (MMP2), metalloproteinase 9 (MMP9) level and human kinase domain insert receptor (KDR) pattern were assayed in mice model. The results showed that patient with MT decreased 5-year survival and higher recurrence or metastasis rate. Compatible with clinical findings, the decreased body weight (30.5 ± 0.65 g) and an increased tumor volume (8.3 ± 1.18 mm3) in MT(+) mice were observed. The increasing signal intensity over lymph node region of hind limb by micro-PET/CT and the tumor cells were detected in lung and bilateral lymph nodes only in MT(+) group. MMP2 (214 ± 9.8 ng/ml) and MMP9 (25.5 ± 1.81 ng/ml) were higher in MT(+) group than in MT(-) group (165 ± 7.8 ng/ml and 16.9 ± 1.40 ng/ml, individually) as well as KDR expression. Taking clinical observations and in vivo evidence together, MT treatment leads to poor prognosis of primary osteosarcoma; physicians should pay more attention on patients who seek MT before diagnosis.
Asunto(s)
Neoplasias Óseas/patología , Metástasis Linfática/patología , Manipulaciones Musculoesqueléticas/efectos adversos , Osteosarcoma/secundario , Adolescente , Animales , Neoplasias Óseas/sangre , Línea Celular Tumoral , Modelos Animales de Enfermedad , Femenino , Humanos , Masculino , Metaloproteinasa 2 de la Matriz/sangre , Metaloproteinasa 9 de la Matriz/sangre , Ratones , Ratones Desnudos , Trasplante de Neoplasias , Osteosarcoma/sangre , Pronóstico , Adulto JovenRESUMEN
STUDY OBJECTIVE: Because the incidence rate of renal impairment is 2-10% for patients treated with high-dose methotrexate and renal impairment develops in 0-12.4% of patients treated for osteosarcoma, we sought to evaluate the efficacy of glucarpidase, a recently approved drug that rapidly hydrolyzes methotrexate to inactive metabolites, which allows for nonrenal clearance in patients with delayed renal methotrexate elimination. DESIGN: Pooled analysis of efficacy data from four multicenter single-arm compassionate-use clinical trials using protocols from 1993 to 2007. PATIENTS: Of 476 patients with renal toxicity and delayed methotrexate elimination who were treated with intravenous glucarpidase for rescue after high-dose methotrexate, 169 patients had at least one preglucarpidase (baseline) plasma methotrexate concentration greater than 1 µmol/L and one postglucarpidase methotrexate concentration measurement by high-performance liquid chromatography and were included in the efficacy analysis; renal recovery was assessed in 436 patients who had at least one recorded preglucarpidase and postglucarpidase serum creatinine concentration measurement. MEASUREMENTS AND MAIN RESULTS: Efficacy was defined as rapid and sustained clinically important reduction (RSCIR) in plasma methotrexate concentration, with a concentration of 1 µmol/L or lower at all postglucarpidase determinations. Median age of efficacy-evaluable patients was 20 years (range 5 weeks-84 years). Osteosarcoma (36%), non-Hodgkin lymphoma (27%), and acute lymphoblastic leukemia (20%) were the most frequent underlying diagnoses. Median preglucarpidase serum methotrexate was 11.7 µmol/L. At the first (median 15 minutes) through the last (median 40 hours) postglucarpidase measurement, plasma methotrexate concentrations demonstrated consistent 99% median reduction. RSCIR was achieved by 83 (59%) of 140 patients. A total of 64% of patients with renal impairment greater than or equal to Common Terminology Criteria for Adverse Events grade 2 recovered to grade 0 or 1 at a median of 12.5 days after glucarpidase administration. CONCLUSION: Glucarpidase caused a clinically important 99% or greater sustained reduction of serum methotrexate levels and provided noninvasive rescue from methotrexate toxicity in renally impaired patients.
Asunto(s)
Lesión Renal Aguda/prevención & control , Antimetabolitos Antineoplásicos/uso terapéutico , Metotrexato/uso terapéutico , gamma-Glutamil Hidrolasa/uso terapéutico , Lesión Renal Aguda/sangre , Lesión Renal Aguda/inducido químicamente , Antimetabolitos Antineoplásicos/administración & dosificación , Antimetabolitos Antineoplásicos/efectos adversos , Antimetabolitos Antineoplásicos/sangre , Neoplasias Óseas/sangre , Neoplasias Óseas/complicaciones , Neoplasias Óseas/tratamiento farmacológico , Ensayos de Uso Compasivo , Esquema de Medicación , Humanos , Leucovorina/administración & dosificación , Leucovorina/uso terapéutico , Metotrexato/administración & dosificación , Metotrexato/efectos adversos , Metotrexato/sangre , Osteosarcoma/sangre , Osteosarcoma/complicaciones , Osteosarcoma/tratamiento farmacológico , Resultado del Tratamiento , gamma-Glutamil Hidrolasa/administración & dosificaciónRESUMEN
Osteosarcoma is a rare malignant bone tumor most commonly occurring in children and young adults presenting with painful swelling. Various etiological factors for osteosarcoma are ionizing radiation, family history of bone disorders and cancer, chemicals (fluoride, beryllium, and vinyl chloride), and viruses. Status of fluoride levels in serum of osteosarcoma is still not clear. Recent reports have indicated that there is a link between fluoride exposure and osteosarcoma. Glycoproteins and glycosaminoglycans are an integral part of bone and prolonged exposure to fluoride for long duration has been shown to cause degradation of collagen and ground substance in bones. The present study was planned to analyze serum fluoride, sialic acid, calcium, phosphorus, and alkaline phosphatase levels in 25 patients of osteosarcoma and age- and sex-matched subjects with bone-forming tumours other than osteosarcoma and musculo-skeletal pain (controls, 25 each). Fluoride levels were analyzed by ISE and sialic acid was analyzed by Warren's method. Mean serum fluoride concentration was found to be significantly higher in patients with osteosarcoma as compared to the other two groups. The mean value of flouride in patients with other bone-forming tumors was approximately 50% of the group of osteosarcoma; however, it was significantly higher when compared with patients of group I. Serum sialic acid concentration was found to be significantly raised in patients with osteosarcoma as well as in the group with other bone-forming tumors as compared to the group of controls. There was, however, no significant difference in the group of patients of osteosarcoma when compared with group of patients with other bone-forming tumors. These results showing higher level of fluoride with osteosarcoma compared to others suggesting a role of fluoride in the disease.
Asunto(s)
Neoplasias Óseas/sangre , Fluoruros/sangre , Ácido N-Acetilneuramínico/sangre , Osteosarcoma/sangre , Adulto , Anciano , Fosfatasa Alcalina/sangre , Calcio/análisis , Niño , Preescolar , Femenino , Humanos , Masculino , Fósforo/análisis , Adulto JovenRESUMEN
PURPOSE: The purpose of this research was to determine whether insulin-like growth factor (IGF) suppression, using a long-acting analogue of somatostatin (OncoLAR, octreotide pamoate long-acting release), will decrease chemotherapy resistance by eliminating an important survival signal to osteosarcoma (OSA) cells in a relevant naturally occurring cancer model. EXPERIMNETAL DESIGN: We conducted a randomized, blinded, placebo-controlled preclinical study in pet dogs with naturally occurring OSA. The study compared primary tumor necrosis and apoptosis, and survival of pet dogs receiving OncoLAR and carboplatin chemotherapy compared with dogs receiving placebo and carboplatin. RESULTS: Dogs receiving OncoLAR had suppression of serum IGF levels by approximately 43% without toxicity. No differences in primary tumor necrosis, apoptosis, tumor IGF mRNA expression, or survival were seen between the dogs receiving OncoLAR plus chemotherapy compared with OncoLAR alone. CONCLUSION: The suppression of IGF levels by the extent and/or duration achieved in the trial was not sufficient to improve chemotherapy-related antitumor effects in pet dogs with OSA.
Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Neoplasias Óseas/tratamiento farmacológico , Factor I del Crecimiento Similar a la Insulina/metabolismo , Osteosarcoma/tratamiento farmacológico , Animales , Apoptosis/efectos de los fármacos , Neoplasias Óseas/sangre , Carboplatino/administración & dosificación , División Celular/efectos de los fármacos , Modelos Animales de Enfermedad , Supervivencia sin Enfermedad , Perros , Evaluación Preclínica de Medicamentos , Femenino , Estudios de Seguimiento , Factor I del Crecimiento Similar a la Insulina/genética , Masculino , Dosis Máxima Tolerada , Octreótido/administración & dosificación , Osteosarcoma/sangre , Distribución Aleatoria , Tasa de Supervivencia , Resultado del TratamientoRESUMEN
PURPOSE: Hemodialysis, hemoperfusion, thymidine, and carboxypeptidase have been recommended together with high-dose (HD) leucovorin (LV) to treat patients at risk for methotrexate (MTX) toxicity. To elucidate the efficacy of high LV rescue as the sole salvage modality for severe MTX intoxication, we studied 13 patients who were treated in this fashion at Memorial Sloan-Kettering Cancer Center (New York, NY). PATIENTS AND METHODS: To identify patients at high risk for severe MTX toxicity, we performed a retrospective review of all patients with MTX levels greater than 100 micromol/L at 24 hours and greater than 10 micromol/L at 48 hours after HD MTX. RESULTS: A total of 13 patients were identified. The median MTX concentration was 164 micromol/L at 24 hours (range, 102 to 940 micromol/L), 16.3 micromol/L at 48 hours (range, 10.5 to 190 micromol/L), and 6.2 micromol/L at 72 hours (range, 1.35 to 39 micromol/L). MTX levels remained greater than 0.1 micromol/L for an average of 11 +/- 3 days (mean +/- SD) (range, 7 to 17 days). In addition to supportive treatment with hydration and sodium bicarbonate administration, all patients were treated solely with HD LV, which was started within the first 24 hours in nine patients, 48 hours in three patients, and 72 hours in one patient in doses that varied from 0.24 to 8 g/d. Significant neutropenia (neutrophil count < 1,000/ microL) occurred in eight patients and lasted for 1 to 5 days. Thrombocytopenia (platelet count < 100,000/microL) occurred in seven patients and lasted for 5 to 10 days. Other toxic manifestations included mucositis of varying degrees, diarrhea, and neutropenic fever, but all patients recovered. CONCLUSION: In the range of MTX levels observed, HD LV can be used as a sole therapy for MTX toxicity without the need for extracorporeal removal and with tolerable morbidity.
Asunto(s)
Antídotos/administración & dosificación , Antimetabolitos Antineoplásicos/envenenamiento , Antagonistas del Ácido Fólico/envenenamiento , Leucovorina/administración & dosificación , Metotrexato/envenenamiento , Antimetabolitos Antineoplásicos/sangre , Neoplasias Óseas/sangre , Neoplasias Óseas/tratamiento farmacológico , Niño , Creatinina/sangre , Esquema de Medicación , Femenino , Antagonistas del Ácido Fólico/sangre , Humanos , Riñón/efectos de los fármacos , Metotrexato/sangre , Neutropenia/inducido químicamente , Neutropenia/tratamiento farmacológico , Osteosarcoma/sangre , Osteosarcoma/tratamiento farmacológico , Estudios Retrospectivos , Trombocitopenia/inducido químicamente , Trombocitopenia/tratamiento farmacológicoRESUMEN
This paper evaluates the influence of pharmacokinetics monitoring of HDMTX in the treatment of localized operable previously untreated high grade osteosarcoma. 44 patients (group 1) received a T10 protocol with dose adapted only to age. 27 other patients (group 2) had a pharmacokinetics monitored dose adaptation of MTX. The pharmacokinetics monitoring leads to higher dosage, higher area under the concentration/time curve and permits higher toxicity to be avoided. The higher dose intensity of MTX gave higher histologic response rate (66% compared to 45%) and higher 5 year disease free survival (92% compare to 76%). HDMTX treatment of osteosarcoma should be dose adapted to indivi-dual pharmacokinetics.
Asunto(s)
Neoplasias Óseas/tratamiento farmacológico , Metotrexato/administración & dosificación , Osteosarcoma/tratamiento farmacológico , Adolescente , Adulto , Neoplasias Óseas/sangre , Neoplasias Óseas/mortalidad , Neoplasias Óseas/cirugía , Quimioterapia Adyuvante , Niño , Preescolar , Terapia Combinada , Supervivencia sin Enfermedad , Relación Dosis-Respuesta a Droga , Femenino , Humanos , Leucovorina/uso terapéutico , Masculino , Metotrexato/efectos adversos , Metotrexato/sangre , Metotrexato/farmacocinética , Metástasis de la Neoplasia , Osteosarcoma/sangre , Osteosarcoma/mortalidad , Osteosarcoma/cirugía , Proyectos Piloto , Pronóstico , Inducción de Remisión , Análisis de Supervivencia , Resultado del TratamientoRESUMEN
In this work we studied 205 children with cancer, aged 6 months to 7 years, who had been diagnosed as suffering from various types of neoplasm. In blood of these children we determined the selenium concentration and glutathione peroxidase activity by fluorometric and spectrophometric methods, respectively. The control group consisted of 128 healthy children. In all groups of children with cancer we observed a significantly lower selenium concentration and lowered glutathione peroxidase activity. We found statistical differences in selenium concentration between first or second and third, and between first and fourth or fifth stages of the disease, only in 3-7 year-old patients. Glutathione peroxidase activity was statistically depressed in the same age group between the first or second and third stages of the disease. Generally, there were no differences in the concentration of the microelement or in the glutathione peroxidase activity between children before and during treatment with cytostatics.
Asunto(s)
Glutatión Peroxidasa/sangre , Neoplasias/sangre , Selenio/sangre , Envejecimiento/sangre , Neoplasias Óseas/sangre , Neoplasias Óseas/enzimología , Niño , Preescolar , Eritrocitos/metabolismo , Femenino , Humanos , Lactante , Neoplasias Renales/sangre , Neoplasias Renales/enzimología , Linfoma/sangre , Linfoma/enzimología , Masculino , Neoplasias/enzimología , Neuroblastoma/sangre , Neuroblastoma/enzimología , Osteosarcoma/sangre , Osteosarcoma/enzimología , Neoplasias Ováricas/sangre , Neoplasias Ováricas/enzimología , Rabdomiosarcoma/sangre , Rabdomiosarcoma/enzimología , Sarcoma de Ewing/sangre , Sarcoma de Ewing/enzimología , Tumor de Wilms/sangre , Tumor de Wilms/enzimologíaRESUMEN
Sixty times of high dose methotrexate (MTX) with citrovorum factor rescue (HDMTX-CF) therapy were applied for 15 patients with osteosarcoma. The serum level of MTX was measured at every 24 hr. by FPIA (Fluorescence Polarization Immuno Assay) method and blood analysis was performed at the same time. Fourtysix parameters were measured in each HDMTX-CF therapy and examined by multiple parameter statistical analyses by a personal computer. In the results, the number of performed chemotherapy, rescue time, serum GOT and creatinine level at 24 hr. were the most relative factors for the change of serum MTX level.
Asunto(s)
Neoplasias Óseas/tratamiento farmacológico , Riñón/fisiopatología , Hígado/fisiopatología , Metotrexato/sangre , Osteosarcoma/tratamiento farmacológico , Adolescente , Adulto , Aspartato Aminotransferasas/sangre , Neoplasias Óseas/sangre , Neoplasias Óseas/fisiopatología , Niño , Preescolar , Creatinina/sangre , Femenino , Humanos , Leucovorina/uso terapéutico , Masculino , Metotrexato/administración & dosificación , Metotrexato/uso terapéutico , Análisis Multivariante , Osteosarcoma/sangre , Osteosarcoma/fisiopatología , Análisis de RegresiónRESUMEN
An 18-year-old female patient receiving adjuvant chemotherapy for osteogenic sarcoma developed a pruritic erythematous rash during infusion of the eighth dose of methotrexate (8 g/m2) in the series. In other respects, the infusion proceeded normally but the 24-hour serum concentration of methotrexate was unexpectedly and extremely high, 574 mumols/L. Dosing error was excluded, as was the hypothesis that the high concentrations were due to the presence of methotrexate-specific antibodies. Acute oliguria and renal failure were the primary manifestations of the drug-induced toxicity and the high concentrations can be attributed to decreased renal elimination of the drug over the first 24 hours. Treatment consisted of folinic acid rescue, forced diuresis, sequential charcoal haemoperfusion and haemodialysis, and repeated oral doses of activated charcoal. After examination of the contribution of the extracorporeal procedures and the charcoal to the elimination of the drug, the relative lack of morbidity was attributed primarily to the folinic acid rescue and the intensive supportive care.
Asunto(s)
Metotrexato/sangre , Osteosarcoma/tratamiento farmacológico , Adolescente , Carbón Orgánico , Diuresis/efectos de los fármacos , Femenino , Semivida , Hemoperfusión , Humanos , Inmunoglobulinas/metabolismo , Leucovorina/uso terapéutico , Leucopenia/inducido químicamente , Metotrexato/envenenamiento , Metotrexato/uso terapéutico , Osteosarcoma/sangre , Unión Proteica , Diálisis RenalRESUMEN
Methotrexate reduces intracellular pools of 5-methyltetrahydrofolate and could result in reduced conversion of homocysteine to methionine by methionine synthetase. This study was designed to investigate the effects of moderate dose to very high dose methotrexate on methionine and total homocysteine as reflections of methotrexate induced intracellular events. Methionine and total homocysteine were measured prior to, during, and following twenty-six 24-h i.v. infusions of 33.6 g/m2 methotrexate (very high dose methotrexate) in 16 children with acute lymphocytic leukemia and seven 4-h i.v. infusions of 8 g/m2 methotrexate (high dose methotrexate) in 5 children with osteogenic sarcoma. Amino acids were measured by gas chromatography/mass spectrophotometry. Mean methionine levels decreased by 70.0 +/- 3.1% (SE) with very high dose methotrexate and 72.6 +/- 5.9% with high dose methotrexate at 24 and 4.5 h, respectively, after beginning methotrexate infusions. Mean total homocysteine levels increased by 61.7 +/- 3.1% with very high dose methotrexate and 55.6 +/- 17.5% with high dose methotrexate at 36 and 24 h, respectively, after beginning methotrexate infusions. No consistent or significant changes were noted in levels of total cysteine, leucine, isoleucine, or valine. Similar changes did not occur in patients receiving prednisone, vincristine, daunomycin, and intrathecal methotrexate as therapy for acute lymphocytic leukemia. These changes in homocysteine and methionine may reflect biological effects of methotrexate that may predict cytotoxicity of methotrexate.
Asunto(s)
Linfoma de Burkitt/tratamiento farmacológico , Homocisteína/sangre , Metionina/sangre , Metotrexato/uso terapéutico , Osteosarcoma/tratamiento farmacológico , Leucemia-Linfoma Linfoblástico de Células Precursoras/tratamiento farmacológico , Adolescente , Adulto , Linfoma de Burkitt/sangre , Niño , Cisteína/sangre , Homocisteína/metabolismo , Humanos , Infusiones Intravenosas , Cinética , Metionina/metabolismo , Metotrexato/administración & dosificación , Modelos Teóricos , Osteosarcoma/sangre , Leucemia-Linfoma Linfoblástico de Células Precursoras/sangreRESUMEN
Three adolescents and one child with osteosarcoma were studied during multiple courses of high-dose methotrexate, citrovorum factor rescue (HDMTX-CFR), with one adolescent treated intermittently over a period of 6 years. Plasma phenylalanine (Phe) and tyrosine (Tyr) were measured immediately before the infusion of MTX and then daily until serum MTX fell below 10(-7) M. At 24 hours, all showed marked increases in Phe and in the Phe/Tyr ratio. This suggests inhibition of dihydropteridine reductase (DHPR) which, in association with hepatic Phe hydroxylase, controls plasma concentrations of Phe. Inhibition of this enzyme system is not relieved by CFR. In the adolescent patients, although MTX levels in plasma declined steadily, Phe concentrations, which fell between 24 and 48 hours, rose to a new peak at 4-7 days. Possible reasons for this secondary increase are discussed. The patient with the longest exposure to HDMTX showed an increase in pretreatment Phe/Tyr ratios with time, suggesting damage to liver parenchymal cells not indicated by standard tests of liver function. Evaluation of plasma Phe during the course of HDMTX-CFR may permit assessment of intracellular concentrations of MTX or its metabolites in the liver without interference by CFR.
Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Neoplasias Óseas/sangre , Osteosarcoma/sangre , Fenilalanina/sangre , Tirosina/sangre , Adolescente , Neoplasias Óseas/tratamiento farmacológico , Niño , Terapia Combinada , Femenino , Humanos , Pierna , Leucovorina/administración & dosificación , Masculino , Metotrexato/administración & dosificación , Osteosarcoma/tratamiento farmacológico , Factores de TiempoRESUMEN
Immediately after intravenous infusion of a high dose (concentration in serum greater than 1000 mumol/L) of methotrexate, the apparent conjugated bilirubin (Bc) concentrations in serum of two osteosarcoma patients, as measured by the Kodak Ektachem 400 analyzer, were greater than the corresponding total bilirubin concentrations, but decreased as the concentrations of methotrexate in serum decreased. In an interference study we found that methotrexate added to sera containing a wide range of basal Bc concentrations increased the measured Bc concentration in a linear and dose-related fashion. Methotrexate also interfered negatively with measurements of unconjugated bilirubin (Bu). The source of the interference appears to be an overlap in the absorption spectrum of methotrexate with Bc and Bu at 400 nm.
Asunto(s)
Bilirrubina/sangre , Metotrexato/sangre , Autoanálisis , Reacciones Falso Positivas , Humanos , Osteosarcoma/sangre , EspectrofotometríaRESUMEN
After 43 cycles of high-dose methotrexate (MTX), the behavior of serum iron was determined. In virtually all cases, typical changes were demonstrated: 8-12 h after termination of treatment there was a sharp increase in serum iron. After 48-60 h, maximum values of 295% (median) of the pretreatment levels were found. Only when the serum MTX had dropped to 6.6 X 10(-8) M, after 62 h (median), did the serum iron level begin to drop; 72 h after termination of treatment the serum iron level had returned to the pretreatment level in only one, and after 108 h, only in 50% of the patients. The marked and persistent rise in serum iron must be considered a consequence of a powerful inhibitory effect of high-dose methotrexate on erythropoiesis. A possible explanation for the particular sensitivity of erythropoiesis to MTX may be the marked storage of MTX, and in particular MTX polyglutamates, in mature erythrocytes and their progenitor cells.
Asunto(s)
Neoplasias Óseas/tratamiento farmacológico , Eritropoyesis/efectos de los fármacos , Hierro/sangre , Metotrexato/efectos adversos , Osteosarcoma/tratamiento farmacológico , Adolescente , Adulto , Neoplasias Óseas/sangre , Relación Dosis-Respuesta a Droga , Femenino , Humanos , Masculino , Metotrexato/sangre , Metotrexato/uso terapéutico , Persona de Mediana Edad , Osteosarcoma/sangreRESUMEN
7-Hydroxy-MTX production after consecutive high-dose MTX therapy (12 g/m2) was measured in 7 patients with osteosarcoma by HPLC. 7-Hydroxy-MTX serum values in the last cycle were found to be significantly lower compared with the first high-dose MTX treatment of the adjuvant chemotherapy protocol (COSS 80). Moreover, in another patient highly reduced 7-hydroxy-MTX production was correlated with severe clinical toxicity. As 7-hydroxy-MTX is a 200 fold less potent dihydrofolic acid reductase inhibitor compared with MTX decreased production of the metabolite may lead to enhanced clinical toxicity which may not be predictable monitoring MTX serum levels alone.
Asunto(s)
Antagonistas del Ácido Fólico/sangre , Metotrexato/análogos & derivados , Metotrexato/administración & dosificación , Cromatografía Líquida de Alta Presión , Humanos , Metotrexato/efectos adversos , Metotrexato/sangre , Osteosarcoma/sangre , Osteosarcoma/tratamiento farmacológico , Factores de TiempoRESUMEN
In an effort to achieve high concentrations and prolonged exposure times, high-dose methotrexate (MTX) was administered by the intra-arterial route over 6 hours at a dose of 12.5 g/m2 to nine patients with osteosarcoma. This was followed by citrovorum factor (CF) rescue, which was initiated 12 hours after completion of the infusion (MTX-CF). The regimen achieved high local concentrations over a finite period. No toxicity was encountered. Treatment was administered at weekly intervals, during which intravenous MTX-CF was interposed if facilities for intra-arterial administration were not available. However, despite increases in local venous concentrations and exposure times, only four of nine patients (44%) responded. This is similar to responses achieved with 7.5 g/m2 (48%) with CF initiated 2 hours after completion of the infusion. Higher MTX doses, intra-arterial administration, and prolongation of cytotoxic exposure time did not confer a therapeutic advantage as opposed to "conventional" intravenous high doses.
Asunto(s)
Metotrexato/administración & dosificación , Osteosarcoma/tratamiento farmacológico , Adolescente , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Niño , Humanos , Infusiones Intraarteriales , Infusiones Parenterales , Leucovorina/administración & dosificación , Metotrexato/sangre , Osteosarcoma/sangre , Osteosarcoma/diagnósticoRESUMEN
Osteosarcoma patients free of CNS metastases are at risk for acquiring leukoencephalopathy after receiving multiple courses of high dose intravenous methotrexate followed by oral leucovorin rescue (MTX-LV). A prospective study of the adequacy of CNS rescue of MTX biochemical toxicity by oral leucovorin was undertaken in newly diagnosed neurologically normal osteosarcoma patients. Prior to surgical resection of the primary tumor, ten patients received 4 weekly courses of MTX-LV. During the fourth weekly MTX-LV treatment, 0 and 72 hr serum and CSF determinations of MTX, 5-methyl-tetrahydrofolate (5-MTHF) and LV were made. No CSF MTX was detectable at 0 hr in any patient, but a significant elevation in CSF MTX occurred in 9/9 patients at 72 hr (mean 47.2 +/- 31.8 ng/ml or 1.04 +/- 0.7 X 10(-7) M). There was no significant change in mean CSF 5-MTHF over 72 hr despite a rise in serum 5-MTHF. MTX exceeded 5-MTHF in 6/9 patients in CSF, whereas only 3/8 patients had higher MTX in the serum at 72 hr. No acute systemic or neurotoxicity was seen. The failure of oral leucovorin to consistently elevate CSF 5-MTHF levels at 72 hr in the context of significant levels of CSF MTX may result in intermittent CNS folate deficiency. The clinical and pathological syndrome of leukoencephalopathy may be related to this phenomenon and may evolve after repeated MTX-LV treatments.